G1 THERAPEUTICS (GTHX) Trading Down 0.8%

Shares of G1 THERAPEUTICS (NASDAQ:GTHX) fell 0.8% during mid-day trading on Monday . The company traded as low as $18.50 and last traded at $20.75. 25,400 shares were traded during mid-day trading, a decline of 70% from the average session volume of 83,814 shares. The stock had previously closed at $20.59.

A number of brokerages recently issued reports on GTHX. Zacks Investment Research lowered shares of G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Cowen and Company restated a “buy” rating on shares of G1 THERAPEUTICS in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $29.75.

Institutional investors have recently added to or reduced their stakes in the business. RA Capital Management LLC acquired a new position in G1 THERAPEUTICS in the second quarter worth $46,813,000. Laurion Capital Management LP acquired a new position in G1 THERAPEUTICS in the second quarter worth $3,488,000. Victory Capital Management Inc. acquired a new position in G1 THERAPEUTICS in the second quarter worth $889,000. Hillhouse Capital Management Ltd. acquired a new position in G1 THERAPEUTICS in the second quarter worth $7,848,000. Finally, FMR LLC acquired a new position in G1 THERAPEUTICS in the second quarter worth $34,093,000. 35.28% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.themarketsdaily.com/2017/11/14/g1-therapeutics-gthx-trading-down-0-8.html.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply